Emicizumab treatment in chronic intermittent haemodialysis

Haemophilia. 2022 Jan;28(1):e20-e22. doi: 10.1111/hae.14446. Epub 2021 Oct 22.

Authors

Maria Weise¹, Annelie Siegemund¹, Lydia Böhme¹, Daniel Grey², Jan Halbritter³, Sirak Petros^{1

4}, Christian Pfrepper¹

Affiliations

¹ Division of Haemostaseology, Department of Haematology, Cellular Therapy and Haemostaseology, University of Leipzig Medical Centre, Leipzig, Germany.
² Dialysis Centre Leipzig "Thomasium", Leipzig, Germany.
³ Division of Nephrology, Department of Internal Medicine, University of Leipzig Medical Centre, Leipzig, Germany.
⁴ Medical ICU, University of Leipzig Medical Centre, Leipzig, Germany.

PMID: 34687109
DOI: 10.1111/hae.14446

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized / therapeutic use
Factor VIII
Hemophilia A*
Humans
Renal Dialysis / adverse effects

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
emicizumab
Factor VIII